“a. You did not retain complete raw data from testing performed to ensure the quality of your APIs. For example, your firm could not provide electronic raw data supporting your High Pressure Liquid Chromatography (HPLC) testing in your Validation Report BP-VR-0701/2010.
b. You failed to retain complete raw data documenting the weights and calculations used in method validation as specified in your standard operating procedure (SOP) “Recording of Raw Data.”
c. Your analyst selectively invalidated data during related substance testing. For example, for [redacted], batch [redacted] on May 15, 2013; you did not retain data from all six injections used for the initial system suitability. Your analyst discarded one of the six injections performed with no justification.
3. Failure to prevent unauthorized access or changes to data and to provide adequate controls to prevent omission of data.
The inadequate controls over access to your data raise questions about the authenticity and reliability of your data and the quality of the APIs you produce. Specifically,
a. Your firm did not have proper controls in place to prevent the unauthorized manipulation of your laboratory’s raw electronic data. Your HPLC computer software lacked active audit trail functions to record changes to analytical methods, including information on original methodology, the identity of the person making the change, and the date of the change. In addition, your laboratory systems did not have access controls to prevent deletion or alteration of raw data. During the inspection, your analysts demonstrated that they were given inappropriate user permissions to delete HPLC data files.
b. Moreover, the gas chromatograph (GC) computer software lacked password protection allowing uncontrolled full access to all employees.”
View the original warning letter.